Your Health. Your Family. Your Choice.
Administered by: Unknown Purchased by: ?
Life Threatening? No
Write-up: This case was received via regulatory authority (Reference number: BE-FAMHP-DHH-N2021-106305) on 17-Sep-2021 and was forwarded to Moderna on 17-Sep-2021. This regulatory authority case was reported by a physician and describes the occurrence of ERYTHEMA, SKIN DISORDER, INJECTION SITE REACTION and LYMPHADENOPATHY in a 13-year-old male patient who received mRNA-1273 (Spikevax) (batch no. 3003659) for COVID-19 vaccination. No Medical History information was reported. On 26-Aug-2021, the patient received first dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On 31-Aug-2021, the patient experienced ERYTHEMA, SKIN DISORDER, INJECTION SITE REACTION and LYMPHADENOPATHY. At the time of the report, ERYTHEMA, SKIN DISORDER, INJECTION SITE REACTION and LYMPHADENOPATHY outcome was unknown. For mRNA-1273 (Spikevax) (Unknown), the reporter did not provide any causality assessments. Concomitant medication was not provided. Treatment information was not provided. Most recent FOLLOW-UP information incorporated above includes: On 17-Sep-2021: The translation document received contains no new information.
Copyright © 2022 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166